Guiding Light: Practical Perspectives of CDK4/6 Inhibitors in HR+/HER2- Metastatic Breast Cancer Guiding Light: Practical Perspectives of CDK4/6 Inhibitors in HR+/HER2- Metastatic Breast Cancer

Expert perspectives on the patient-centric management of HR+/HER2- metastatic breast cancer with CDK4/6 inhibitors, latest clinical data and its relevance to daily practice.Medscape Medical Affairs
Source: Medscape Today Headlines - Category: Consumer Health News Tags: None Virtual Symposium Source Type: news